TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 294 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q1 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,111 | +19.2% | 2,205 | +21.0% | 0.01% | +20.0% |
| Q2 2023 | $28,624 | -3.2% | 1,822 | +1.5% | 0.01% | 0.0% |
| Q1 2023 | $29,582 | +17.3% | 1,795 | +11.0% | 0.01% | 0.0% |
| Q4 2022 | $25,225 | +20.1% | 1,617 | -0.1% | 0.01% | +25.0% |
| Q3 2022 | $21,000 | -12.5% | 1,618 | -5.2% | 0.00% | -20.0% |
| Q2 2022 | $24,000 | +9.1% | 1,707 | +11.2% | 0.01% | +25.0% |
| Q1 2022 | $22,000 | +37.5% | 1,535 | +26.9% | 0.00% | +33.3% |
| Q4 2021 | $16,000 | +100.0% | 1,210 | +139.6% | 0.00% | +50.0% |
| Q3 2021 | $8,000 | +14.3% | 505 | +16.4% | 0.00% | +100.0% |
| Q2 2021 | $7,000 | +40.0% | 434 | +68.2% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -64.3% | 258 | -67.5% | 0.00% | -50.0% |
| Q4 2020 | $14,000 | +366.7% | 794 | +351.1% | 0.00% | +100.0% |
| Q3 2020 | $3,000 | +200.0% | 176 | +193.3% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 60 | -20.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 75 | +92.3% | 0.00% | – |
| Q4 2019 | $1,000 | – | 39 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 8,958,784 | $176,757,000 | 33.75% |
| Ovata Capital Management Ltd | 879,800 | $17,557,092,000 | 13.04% |
| Paulson & Co. | 13,244,711 | $261,318,000 | 5.64% |
| Glenview Capital Management | 30,582,721 | $603,397,000 | 5.28% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 718,028 | $14,167,000 | 4.85% |
| Velanne Asset Management Ltd | 302,694 | $5,972,000 | 3.52% |
| Blackcrane Capital, LLC | 172,708 | $3,408,000 | 2.72% |
| Melqart Asset Management (UK) Ltd | 1,557,000 | $30,720,000 | 2.57% |
| GMT CAPITAL CORP | 3,345,976 | $66,016,000 | 2.55% |
| REDWOOD CAPITAL MANAGEMENT, LLC | 827,955 | $16,336,000 | 2.24% |